Evaluating Using Rescue Therapies for CAR T cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
Enrolling By Invitation
18-99 years
All
Phase
N/A
20 participants needed
1 Location
Brief description of study
This research study is being conducted to evaluate experimental rescue therapies for the treatment of cytokine release syndrome (CRS) and CAR T cell related HLH-like syndrome (CRHLS). These are both life-threatening side effects which can occur in some patients after infusion with a CAR T cell product. This consent allows for the use of an experimental drug called Tadekinig alfa, which may help improve CRS and CRHLS side effects. Experimental drugs are not approved by the FDA and are considered investigational. You may also be consented/enrolled to receive Tadekinig alfa prior to your CAR T cell infusion in anticipation of any serious side effects.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: CART,cytokine
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 850925
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
